Indications And Dose
Improvement of walking disability in multiple sclerosis (specialist use only) ▶BY MOUTH ▶Adult: 10 mg every 12 hours, discontinue treatment if no improvement within 2 weeks
PDF page 917
Loading InternPractice…
Drug reference
Improvement of walking disability in multiple sclerosis (specialist use only) ▶BY MOUTH ▶Adult: 10 mg every 12 hours, discontinue treatment if no improvement within 2 weeks
PDF page 917
History of seizures (discontinue treatment if seizures occur)
PDF page 917
Atrioventricular conduction disorders. predisposition to seizures. sinoatrial conduction disorders . symptomatic cardiac rhythm disorders
PDF page 917
Dispense in original container (pack contains a desiccant) and discard any tablets remaining 7 days after opening.
PDF page 917
Scottish Medicines Consortium (SMC) decisions SMC No. SMC2253 The Scottish Medicines Consortium has advised (April 2020) that fampridine (Fampyra ®) is accepted for use within NHS Scotland for the improvement of walking in adults with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4 to 7). This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower. All Wales Medicines Strategy Group (AWMSG) decisions AWMSG No. 3942 The All Wales Medicines Strategy Group has advised (December 2019) that fampridine (Fampyra ®) is recommended as an option for use within NHS Wales for the improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale [EDSS] 4 to 7). This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
PDF page 917
→Appendix 1: fampridine
PDF page 917
▶Common or very common Anxiety. asthenia. balance impaired. constipation. dizziness. dyspepsia. dyspnoea. headache. insomnia. laryngeal pain. nausea. pain. palpitations. paraesthesia. tremor. urinary tract infection . vomiting ▶Uncommon Seizure. skin reactions. tachycardia
PDF page 917
Avoid—toxicity in animal studies.
PDF page 917
Avoid—no information available.
PDF page 917
Avoid if eGFR less than 80 mL/minute/1.73 m2.
PDF page 917
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule Modified-release tablet CAUTIONARY AND ADVISORY LABELS 23, 25 ▶Fampyra (Biogen Idec Ltd) Fampridine 10 mg Fampyra 10mg modified-release tablets | 28 tablet P £181.00 (Hospital only) | 56 tablet P £362.00 (Hospital only) IMMUNOSTIMULANTS › INTERFERONS
PDF page 917
10 mg every 12 hours, discontinue treatment if
First-line fragment. Read the complete Indications and Dose section above.
PDF page 917